SMYTH MARK,GOLDMAN ERICK,WIRTH DAVID D.,PURRO NORBERT
申请号：
CL2014003306
公开号：
CL2014003306A1
申请日:
2014.12.03
申请国别(地区):
CL
年份:
2015
代理人:
摘要：
Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.<；p>；COMPOSICIÓ；N FARMACÉ；UTICA ORAL QUE COMPRENDE (A) 40-200 mg DE 1-((R)-3-(4-AMINO-3-(4-FENOXIFENIL)-1H-PIRAZOLO[3,4-d]PIRIMIDIN-1-IL)PIPERIDIN-1-IL)2-PROPEN-1-ONA (IBRUTINIB), (B) 40-50% EN PESO DE UN DILUYENTE, (C) 3-10% EN PESO DE UN AGENTE DESINTEGRADOR, (D) 2-7% EN PESO DE UN AGENTE DE ACTIVIDAD SUPERFICIAL, Y (E) 0,2-1,0% EN PESO DE UN LUBRICANTE, Ú；TIL PARA TRATAR CÁ；NCER.<；/p>；
